Press Releases from 2010

Reinach, Switzerland, 16 December 2010 – Evolva Holding SA (SIX: EVE), today announced it has initiated a multiple ascending dose Phase I clinical study with an extended release oral formulation of EV-077.

Reinach, Switzerland, 13 December 2010 – Evolva Holding SA (SIX: EVE) today announced that a group of core shareholders, holding in total approx. 114.4 million shares, equal to 82.2% of Evolva Holding SA’s share capital, have agreed to partially extend the lock-up on their current holdings until 1 September 2011, through a staggered release and a coordinated sale of shares. The aim is to increase the free float and to achieve an orderly unwinding of the lock-up.

The research will run for a minimum of two years and primarily be located at Evolva’s Denmark and India sites. Around ten scientists from Evolva will be engaged on the program. Abunda will provide the majority of the funding and Evolva will be entitled to a double-digit share of the total commercial returns from the project. Further details regarding the agreement remain undisclosed. The new agreement does not change Evolva’s revenue forecast for 2010.

Reinach, Switzerland, 13 September 2010 – Evolva Holding SA (SIX: EVE) today announced its interim results for the period 1 January to 30 June 2010.

Highlights

  • Revenues increased to CHF 9.4 million (2009: CHF 7.8 million)

  • Net loss for the first six months was CHF 11.4 million (2009: CHF 3.4 million)

Reinach, Switzerland, 27 August 2010 - Evolva Holding SA (SIX: EVE) today announces that its CEO, Neil Goldsmith, received the Biotech Builders Award for 2010 at the annual Biotech Builders meeting yesterday evening.

Reinach, Switzerland, 2 July 2010 - Evolva Holding SA (SIX: EVE) today announces that Ventureast Trustee Company (P) Limited (“Ventureast”) and APIDC Venture Capital (P) Limited (“APIDC”) have provided CHF 3.5 million of fresh funds to Evolva. This is in line with the commitment that the two investors made in December 2009.

Evolva Biotech Private Limited (“Evolva India”) is a majority-owned subsidiary of the Evolva group. The unit works on the creation of gene libraries and synthetic and analytical chemistry. In addition, it works on industrial projects and informatics. At the end of 2009, the unit employed 23 people. Evolva India has recently moved from Hyderabad to the Ticel Bio Park in Chennai.

Reinach, Switzerland, 18 June 2010 – Evolva Holding SA (SIX: EVE) today announced that Dr. Jessica Mann will resign as Chief Medical Officer of Evolva as of 31 July 2010 to take up a Senior Development position as Head of Translational Medicine at Hoffman La Roche.

Reinach, Switzerland, 10 June 2010 – Evolva Holding SA (SIX: EVE) The Annual General Meeting of Evolva Holding SA has approved the proposals that were put forward by the Board of Directors.

Reinach, Switzerland, 2 June 2010 – Evolva Holding SA (SIX: EVE) today announced that Dr. Melya Hughes Crameri, CEO of Evolva’s US subsidiary Genetic Chemistry, has resigned from her role effective June 18th, in order to pursue other opportunities. Dr.

Contact Information

Evolva SA
Duggingerstrasse 23
CH-4153 Reinach
Switzerland
Tel: +41 61 485 2000
Fax: +41 61 485 2001
Evolva A/S
Lersoe Parkallé 42-44
DK-2100 Copenhagen OE
Denmark
Tel: +45 35 200 230
Fax: +45 35 200 231
Evolva Biotech Private Limited
401 - 405, 4th Floor
Ticel Bio Park Ltd
Taramani Road, Taramani
Chennai 600 113
Tamil Nadu, India
Tel: +91 44 4297 1050
Fax: +91 44 4297 1060
Evolva, Inc. (Evolva USA)
2440 Embarcadero Way
Palo Alto
CA 94303
USA
Tel: +1 650 856 2436
Fax: +1 650 856 7950

General Enquiries: info@evolva.com • Business Enquiries: busdev@evolva.com • India Enquiries: info_india@evolva.com